SAVOIR trial: Savolitinib versus Sunitinib in patients with MET-driven papillary renal cell carcinoma
Papillary renal cell carcinoma ( PRCC ) is the most common type of non-clear cell RCC, accounting for 10–15% of renal malignancies.
As a subset of PRCC cases are MET-driven, MET inhibition may be an appropriate targeted treatment approach.
In a single-arm phase II study, Savolitinib, a highly selective MET-tyrosine kinase inhibitor, demonstrated antitumor activity in patients with MET-driven PRCC ( Choueiri et al. JCO 2017 ).
The phase III SAVOIR study further assessed Savolitinib versus standard of care Sunitinib in patients with MET-driven papillary renal cell carcinoma.
In this open-label ( sponsor blinded ), randomized study, patients with centrally confirmed MET-driven ( MET and/or HGF amplification, chromosome 7 gain and/or MET kinase domain mutations ), metastatic papillary renal cell carcinoma were randomized to Savolitinib 600 mg once daily ( QD ), or Sunitinib 50 mg QD 4 weeks on / 2 weeks off.
Primary objective was progression-free survival ( PFS; RECIST 1.1 by blinded independent central review ).
Secondary objectives included overall survival ( OS ), objective response rate ( ORR ), and safety and tolerability.
After external data on predicted progression-free survival with Sunitinib in patients with MET-driven disease became available, study enrollment was closed.
At data cutoff ( Aug 2019 ), only 60 of the planned 180 patients were randomized ( Savolitinib n = 33; Sunitinib n = 27 ).
Most had chromosome 7 gain ( Savolitinib 91%; Sunitinib 96% ) and no prior therapy ( Savolitinib 85%; Sunitinib 93% ).
Progression-free survival, overall survival, and objective response rate were numerically improved with Savolitinib versus Sunitinib: PFS 7.0 vs 5.6 months; OS NR ( not reached ) vs 13 months; ORR ( all partial responses ) 27% vs 7%.
CTCAE grade greater than or equal to 3 adverse events were reported in 42% and 81% of patients; dose modifications were related to adverse effects in 30% and 74% of patients with Savolitinib and Sunitinib respectively.
After discontinuation, 36% of all Savolitinib and 19% of all Sunitinib patients received subsequent anticancer therapy.
In conclusion, although patient numbers and follow-up were limited, Savolitinib demonstrated encouraging efficacy and an improved safety profile versus Sunitinib, with fewer grade 3 or more adverse effects and fewer dose modifications required.
Sunitinib performance was poorer than expected based on external retrospective. ( Xagena )
Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...